In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Kala Pharmaceuticals Inc (NASDAQ: KALA), with a price target of $51. The company’s shares opened today at $8.49, close to its 52-week low of $7.60.
According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -2.3% and a 39.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Kala Pharmaceuticals Inc is a Strong Buy with an average price target of $32.67, which is a 284.8% upside from current levels. In a report issued on October 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $32 price target.
The company has a one-year high of $22.78 and a one-year low of $7.60. Currently, Kala Pharmaceuticals Inc has an average volume of 305.2K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KALA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kala Pharmaceuticals, Inc. is a biopharmaceutical company, focused on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.
Read More on KALA: